Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, ...
BOCA RATON, Fla., August 28, 2025--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology clinical trial matching, today announced the launch of its new key feature on the Patient Connect app.
SAN DIEGO--(BUSINESS WIRE)--Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a ...
Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials. The consortium, founded in 2022, is focused on ...
Massive Bio launches Patient Connect & DrArturoAI, delivering on CMS's vision with AI trial matching, secure data access & full interoperability compliance. We salute CMS for spearheading a ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
NEW YORK — Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results